Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

U.S. FDA Approves Glaxosmithkline Plc And Joint Venture's HIV Drug Tivicay-Reuters


Monday, 12 Aug 2013 06:38pm EDT 

Reuters reported that The U.S. Food and Drug Administration said it has approved GlaxoSmithKline Plc's drug Tivicay to treat a common strain of HIV, the virus that causes AIDS. The once-daily drug, known generically as dolutegravir, belongs to a novel class known as integrase inhibitors that block the virus from entering cells. Tivicay is owned by ViiV Healthcare, an HIV joint venture between GSK, Pfizer Inc and Shionogi & Co Ltd in which GSK is the largest shareholder, with a 76.5% stake. 

Company Quote

45.01
0.05 +0.11%
23 Jan 2015